There has been an exponential increase in the volume and quality of published research relating to breast disease over the past decades. This book identifies the 50 key scientific articles in the field of breast disease and breast surgery and examines their importance and impact on current clinical care.
Among thousands of articles, a small fraction are truly 'game changing'. Such studies form the foundations of breast surgery today, and the selection of papers within this book provide the 50 landmark papers every 21st-century breast surgeon needs to know. A commentary to each carefully selected paper explains why these papers are so important, thus providing every surgeon with the foundation stones of knowledge in this fast-moving area.
A valuable reference not only to the established surgeon, but also to breast surgery residents and trainees, as well as to more experienced surgeons as they continue to learn new techniques and approaches and to improve their knowledge of breast disease and treatments. The papers provide an evidence-based resource for those surgeons preparing for professional exams and may inspire clinicians to produce new research.
Edited by:
Lynda Wyld,
Ramsey Cutress,
Jenna Morgan
Imprint: CRC Press
Country of Publication: United Kingdom
Dimensions:
Height: 229mm,
Width: 152mm,
Weight: 1.650kg
ISBN: 9781032522388
ISBN 10: 1032522380
Series: 50 Landmark Papers
Pages: 290
Publication Date: 15 April 2024
Audience:
Professional and scholarly
,
Undergraduate
Format: Hardback
Publisher's Status: Active
Section One: Epidemiology 1. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence Collaborative Group on Hormonal Factors in Breast Cancer 2. Moderate Alcohol Intake and Cancer Incidence in Women Allen N, Beral V, Cassabone D, Kan SW, Reeves GK, Brown A, Green J on behalf of the Million Women Study Collaborators Section Two: Screening and Prevention 3. 3. Tamoxifen for Prevention of Breast Cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (NASBP P-1) Fisher B, Costantino J, Wickerman D, et al 4. 4. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. Tabar L, Fagerberg G, Duffy SW, et al 5. 5. The benefits and harms of breast cancer screening: an independent review Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. Section Three: Diagnostic Imaging 6. 6. Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening (DMIST) Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, D’Orsi C, Jong R, Rebner M 7. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) Leach MO, Boggis CRM, Dixon AK, Easton DF, et al 8. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial Turnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, Hanby A, Brown J Section Four: Surgery: Mastectomy versus conservation 9. 9. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N 10. The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast Conserving Therapy: A Meta-Analysis Houssami N, Macaskill P, Marinovich ML, Morrow M 11. Ten year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study van Maaren MC, de Munck L, de Back GH, Jobsen J, van Dalen T, Poortmans P, Strobbe LC, Siesling S. Section Five: De-escalation of Axillary Surgery 12. 12. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N 13.13. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. Giuliano AE, Ballman KV, McCall L, et al. 14. 14. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Donker M, van Tienhoven G, Straver ME, et al 1515. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial Boughey JC, Suman VJ, Mittendorf EA, et al. Section Six: Oncoplastic Breast Surgery / Breast Reconstruction 16. 16. Planning and use of therapeutic mammaplasty-Nottingham approach S J McCulley and R D Macmillan 17.17. Oncoplastic breast‐conserving surgery for women with primary breast cancer Nanda A, Hu J, Hodgkinson S, Ali S, Rainsbury R, Roy PG. 18.18. Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study Potter et al 19.19. Improving Breast Cancer Surgery: A Classification and Quadrant per Quadrant Atlas for Oncoplastic Surgery Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM Section Seven: Breast cancer genomics and prognostic tools 20.20. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Therese Sørlie, Charles M. Perou, Robert Tibshirani, Turid Aas, Stephanie Geisler, Hilde Johnsen, et al. 21.21. Comprehensive molecular portraits of human breast tumours The cancer Genome Atlas Network 2222. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Fatima Cardoso, Laura J. van’t Veer, Jan Bogaerts, et al for the MINDACT investigators 23. 23. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (RxPonder) K. Kalinsky, W.E. Barlow, J.R. Gralow, et al 24.24. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer Gordon C Wishart, Elizabeth M Azzato, David C Greenberg, Jem Rashbass, Olive Kearins, Gill Lawrence, Carlos Caldas, and Paul DP Pharoah Section Eight: Ductal Carcinoma In Situ 25 25. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Esther H. Lips, Tapsi Kumar, Anargyros Megalios, Lindy L. Visser, Michael Sheinman, Angelo Fortunato, et al 26.26. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the Sloane Project Shaaban AM, Hilton B, Clements K, Provenzano E, Cheung S, Wallis MG, Sawyer ES, Thomas JS, Hanby AM, Pinder SE, Thompson AM 27. 27. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD 28. 28. A prognostic index for ductal carcinoma in situ of the breast. Silverstein MJ, Poller D, Craig PH, et al Section Nine: Adjuvant Chemotherapy 29. 29. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., Cutter, D., Darby, S., McGale, P., Taylor, C., Wang, Y. C., Bergh, J., Di Leo, A., Albain, K., Swain, S., Piccart, M., & Pritchard, K 30. 30. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. CREATE-X N Masuda, Soo-Jung Lee, S Ohtani, Y-H Im, E-S Lee, I Yokota, K Kuroi, S-A Im, B-W Park, S-B Kim, Y Yanagita, and S Ohno et al Section Ten: Adjuvant Endocrine Therapy 31. 31. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 32.32. Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor – positive breast cancer: ATLAS, a randomised trial C Davies et al 33. 33. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer Prudence A Francis et al 34.34. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial ATAC Trialist’s Group Section Eleven: Immunotherapy / Systemic Therapy 35. 35. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al & Herceptin Adjuvant (HERA) Trial Study Team 36.36. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer Tutt ANJ, Garber JE, Kaufman B, et al 37.37. Pembrolizumab for Early Triple-Negative Breast Cancer Schmid, P., et al 38.38. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer von Minckwitz, Huang, Mano, et al. for the KATHERINE Investigators Section Twelve: Adjuvant Radiotherapy 39.39. Breast-conserving surgery with or without irradiation in early breast cancer (PRIME II). Ian H Kunkler et al 40.40. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 41.41. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. H Bartelink et al 42.42. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 43.43. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects; results from a multicentre, non-inferiority, randomised, phase 3 trial. Brunt AM, et al Section Thirteen: Bisphosphonates 44.44. Zoledronic acid as adjuvant therapy for breast cancer (does Adjuvant Zoledronic acid redUce REcurrence in patients with high risk, localised breast cancer), the AZURE trial Robert Coleman, David Cameron, David Dodwell, et al on behalf of the AZURE investigators. 45.45. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial Eastell, R., Adams, J., Clack, G., Howell, A., Cuzick, J., Mackey, J., Beckmann, M. W., & Coleman, R. E. Section Fourteen: Surgery for Metastatic Disease 46. 46. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Rajendra Badwe, Rohini Hawaldar, Nita Nair, Rucha Kaushik, Vani Parmar, Shabina Siddique, Ashwini Budrukkar, Indraneel Mittra, Sudeep Gupta Section Fifteen: Breast Cancer in Pregnancy / Prophylactic surgery for family history 47.47.Treatment of breast cancer during pregnancy: an observational study Loibl S, Han SN, Minckwitz GV, Bontenbal M, Ring A, Giermek J et al 48.48. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study Ellen R Copson, Tom C Maishman, Will J Tapper, Ramsey I Cutress, Stephanie Greville-Heygate, Douglas G Altman et al 49.49. Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer. Hartmann L., Schaid D., Woods J., Crotty T., Myers J., Arnold P.et al 50. 50. Wire- and magnetic-seed-guided localization of impalpable breast lesions: iBRA-NET localisation study (Arm 1) Rajiv V Dave, Emma Barrett, Jenna Morgan, et al on behalf of the iBRA-NET Localisation Study collaborative
Lynda Wyld is Professor of Surgical Oncology at the University of Sheffield and a Consultant Oncoplastic Surgeon at Doncaster and Bassetlaw Teaching Hospitals. She is the Past President of the British Association of Surgical Oncology (BASO) and Past Chair of the European Society of Surgical Oncology (ESSO) Education Committee and is a Trustee of the Association of Breast Surgery (ABS). Ramsey Cutress is Professor of Breast Surgery at University of Southampton and a Consultant Surgeon at University Hospital Southampton. He is Chair of the Association of Breast Surgery (ABS) Academic and Research Committee, Course Director for the ABS Advanced Skills in Breast Disease Management course, Head of the School for Clinical Academic Training at the Wessex Deanery and breast disease subspecialty editor for the Annals of the Royal College of Surgeons of England, demonstrating his interests in research and teaching. Jenna Morgan Jenna is an NIHR Advanced Fellow Breast Surgery at the University of Sheffield and a Consultant Oncoplastic Surgeon at the Jasmine Breast Unit in Doncaster, UK. She is Past Chair of the Mammary Fold Academic Committee of the ABS. She is a clinical academic with an interest in mixed methods research, geriatric oncology and the psychology or ageing in healthcare settings.
Reviews for 50 Landmark Papers every Breast Surgeon Should Know
'Laudable goals, and the book amply fulfills them... the book is compact but dense with information, readable, and affordable.' 'The papers are all written by stellar authorities and are truly practice-changing. It will serve as a useful resource and teaching tool'. Score: 94 -Carol Scott-Conner, MD, PhD, MBA, MFA
